PMGC announces closing of Elevai skincare divestiture
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 16 2025
0mins
Should l Buy ELAB?
Divestiture Announcement: PMGC (ELAB) has successfully closed the sale of its wholly owned subsidiary, Elevai Skincare, to Carmell Corporation (CTCX) as part of a definitive purchase agreement.
Strategic Focus: The company reaffirms its commitment to enhancing shareholder value and market leadership following this significant divestiture in its journey as a diversified holding company.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ELAB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ELAB
About ELAB
PMGC Holdings Inc. is a diversified holding company. Its wholly owned subsidiaries include Northstrive Biosciences Inc., PMGC Capital LLC, Pacific Sun Packaging, Inc. AGA Precision Systems LLC and NorthStrive Defense Tech LLC. Northstrive Biosciences Inc. is a biopharmaceutical company focusing on the development and acquisition of aesthetic medicines and therapeutic products. PMGC Capital LLC is a multi-strategy investment firm focused on direct investments, strategic lending, and acquiring undervalued companies and assets across diverse markets. Pacific Sun Packaging, Inc. is a specialty packaging provider focused on high-precision, component-level packaging solutions for the electronics and information technology hardware industries. AGA Precision Systems LLC is a specialized computer numerical control machine shop. NorthStrive Defense Tech LLC is focused on identifying, acquiring, and commercializing advanced defense technologies, with an emphasis on drone and autonomous systems.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
NorthStrive Files New Patent for Muscle Loss Treatment
- Patent Application Expansion: NorthStrive Biosciences has filed a new U.S. patent application (Application No. 19/655,160) aimed at expanding its proprietary EL-22 technology into human pharmaceutical applications, particularly for patients suffering from muscle loss, showcasing the company's innovative potential in the biopharmaceutical sector.
- Clear Therapeutic Targets: The patent covers specific dosing regimens and formulations targeting muscle-wasting conditions such as sarcopenia and certain neurological disorders, indicating the company's commitment to addressing a wide range of muscle health issues with significant market demand.
- Strengthened IP Strategy: This filing not only enhances NorthStrive's intellectual property portfolio but also reflects the company's ongoing focus on muscle health therapeutics, potentially providing strong support for future market competition.
- Broad Market Prospects: As NorthStrive's lead asset, EL-22 leverages a myostatin-engineered probiotic approach, expected to offer new solutions for patients undergoing weight loss treatments, further expanding its influence in the biopharmaceutical and adjacent markets.
See More
NorthStrive Defense Tech Secures Patent License for Navigation Technology
- License Agreement: NorthStrive Defense Tech has signed an exclusive option agreement with a corporation to secure a license for U.S. Patent No. 12,277,716 B2, aimed at addressing the navigation capability gap for drones in GPS-jammed or denied environments, which is expected to significantly enhance its competitiveness in the defense and drone markets.
- Market Potential: According to Technavio, the GPS-denied drone navigation market is projected to grow at a CAGR of 31.7% through 2030, and NorthStrive's technology aligns perfectly with this demand, potentially attracting substantial investment and partnership opportunities.
- Diverse Application Prospects: This technology is applicable not only for U.S. Department of Defense and NATO operations in electronic warfare and counter-drone missions but also extends to urban commercial delivery and infrastructure monitoring, showcasing its broad market adaptability and strategic value.
- Future Development Plans: The agreement outlines an evaluation period during which NorthStrive will validate use cases and engage with potential strategic and government partners, and if successful, will advance the technology's commercialization process, further solidifying its market position.
See More
Univest Closes $40 Million Equity Line Facility for PMGC Holdings
- Financing Size: Univest Securities has closed a $40 million equity financing for PMGC Holdings, with an initial tranche of $10 million aimed at supporting the company's acquisition strategy in the U.S. precision manufacturing sector, thereby enhancing its market competitiveness.
- Financing Structure: The financing is structured through a purchase agreement where PMGC Holdings agrees to issue and sell common stock to the investor, which is expected to provide essential funding for the company's expansion and growth of its diversified portfolio.
- Compliance Requirements: The shares from this financing will be issued via a private placement and are not registered under securities laws, requiring PMGC Holdings to file a registration statement with the SEC to cover the resale of common stock, ensuring compliance and reducing legal risks.
- Market Impact: As the sole placement agent, Univest, with its strong reputation on Wall Street and experience in raising over $1.7 billion, is expected to provide robust support for PMGC Holdings' future financing activities, further driving its business development.
See More
Univest Closes $40 Million Equity Line Facility for PMGC Holdings
- Financing Size: Univest Securities has closed a $40 million equity financing agreement with PMGC Holdings, with an initial tranche of $10 million aimed at supporting the company's acquisition strategy in the U.S. precision manufacturing sector, thereby enhancing its market competitiveness.
- Financing Structure: The financing is structured through a prepaid purchase agreement under which PMGC Holdings will issue common stock to meet investor demand, providing the company with a flexible funding source that can accelerate its expansion plans.
- Compliance Requirements: The shares involved in this financing will be privately placed under Section 4(a)(2) and Rule 506(b) of the Securities Act of 1933, meaning they are not registered and cannot be publicly sold in the U.S. without SEC registration, ensuring compliance with regulatory standards.
- Market Impact: Univest has successfully raised over $1.7 billion in capital for issuers globally since 2019, and this transaction further solidifies its position on Wall Street while potentially opening new growth opportunities for PMGC Holdings.
See More
SVM Machining Signs Long-Term Agreement with Turbo-Jet Products
- Long-Term Agreement Signed: SVM Machining's execution of a long-term agreement with Turbo-Jet Products will supply mission-critical aerospace and defense components, ensuring stable supply over the next five years, thereby enhancing SVM's position within the aerospace supply chain.
- Strategic Partnership: The agreement not only provides a framework for future purchase orders but also supports compliance with U.S. government and defense-related contracts, demonstrating SVM's commitment to meeting stringent regulations.
- Quality Certification Progress: SVM registered under the International Traffic in Arms Regulations (ITAR) as of March 20, 2026, and is actively pursuing AS9100 certification, which is expected to further enhance its competitiveness in regulated defense programs.
- Diverse Business Support: As a wholly-owned subsidiary of PMGC Holdings, SVM supports multiple critical industries, including medical technology, aerospace, and semiconductors, showcasing its robust production capabilities in a diversified market.
See More
PMGC Secures $40 Million Funding to Boost Acquisition Plans
- Funding Boost for Acquisitions: PMGC Holdings announced a $40 million equity purchase facility, with an initial tranche of approximately $10 million aimed at acquisitions, automation investments, and workforce development, enhancing its market position in the aerospace and defense sectors.
- Stock Price Rebound: Following the funding announcement, ELAB shares rose over 8% in morning trading on Friday, poised to end a three-session losing streak that had seen a decline of around 25%, indicating market confidence in the company's growth potential.
- Expansion Strategy: Since 2025, PMGC has expanded through acquisitions, adding three CNC precision manufacturing businesses and a specialty IT packaging firm, which strengthens its capabilities in complex machining and medical applications, thereby solidifying its competitive edge in the market.
- Market Sentiment Analysis: Despite the positive funding news, retail sentiment on Stocktwits remains bearish, reflecting the stock's recent underperformance, with a nearly 90% decline this year, as concerns about dilution threaten the capital structure.
See More
NorthStrive Files New Patent for Muscle Loss Treatment
- Patent Application Expansion: NorthStrive Biosciences has filed a new U.S. patent application (Application No. 19/655,160) aimed at expanding its proprietary EL-22 technology into human pharmaceutical applications, particularly for patients suffering from muscle loss, showcasing the company's innovative potential in the biopharmaceutical sector.
- Clear Therapeutic Targets: The patent covers specific dosing regimens and formulations targeting muscle-wasting conditions such as sarcopenia and certain neurological disorders, indicating the company's commitment to addressing a wide range of muscle health issues with significant market demand.
- Strengthened IP Strategy: This filing not only enhances NorthStrive's intellectual property portfolio but also reflects the company's ongoing focus on muscle health therapeutics, potentially providing strong support for future market competition.
- Broad Market Prospects: As NorthStrive's lead asset, EL-22 leverages a myostatin-engineered probiotic approach, expected to offer new solutions for patients undergoing weight loss treatments, further expanding its influence in the biopharmaceutical and adjacent markets.
See More
NorthStrive Defense Tech Secures Patent License for Navigation Technology
- License Agreement: NorthStrive Defense Tech has signed an exclusive option agreement with a corporation to secure a license for U.S. Patent No. 12,277,716 B2, aimed at addressing the navigation capability gap for drones in GPS-jammed or denied environments, which is expected to significantly enhance its competitiveness in the defense and drone markets.
- Market Potential: According to Technavio, the GPS-denied drone navigation market is projected to grow at a CAGR of 31.7% through 2030, and NorthStrive's technology aligns perfectly with this demand, potentially attracting substantial investment and partnership opportunities.
- Diverse Application Prospects: This technology is applicable not only for U.S. Department of Defense and NATO operations in electronic warfare and counter-drone missions but also extends to urban commercial delivery and infrastructure monitoring, showcasing its broad market adaptability and strategic value.
- Future Development Plans: The agreement outlines an evaluation period during which NorthStrive will validate use cases and engage with potential strategic and government partners, and if successful, will advance the technology's commercialization process, further solidifying its market position.
See More
Univest Closes $40 Million Equity Line Facility for PMGC Holdings
- Financing Size: Univest Securities has closed a $40 million equity financing for PMGC Holdings, with an initial tranche of $10 million aimed at supporting the company's acquisition strategy in the U.S. precision manufacturing sector, thereby enhancing its market competitiveness.
- Financing Structure: The financing is structured through a purchase agreement where PMGC Holdings agrees to issue and sell common stock to the investor, which is expected to provide essential funding for the company's expansion and growth of its diversified portfolio.
- Compliance Requirements: The shares from this financing will be issued via a private placement and are not registered under securities laws, requiring PMGC Holdings to file a registration statement with the SEC to cover the resale of common stock, ensuring compliance and reducing legal risks.
- Market Impact: As the sole placement agent, Univest, with its strong reputation on Wall Street and experience in raising over $1.7 billion, is expected to provide robust support for PMGC Holdings' future financing activities, further driving its business development.
See More
Univest Closes $40 Million Equity Line Facility for PMGC Holdings
- Financing Size: Univest Securities has closed a $40 million equity financing agreement with PMGC Holdings, with an initial tranche of $10 million aimed at supporting the company's acquisition strategy in the U.S. precision manufacturing sector, thereby enhancing its market competitiveness.
- Financing Structure: The financing is structured through a prepaid purchase agreement under which PMGC Holdings will issue common stock to meet investor demand, providing the company with a flexible funding source that can accelerate its expansion plans.
- Compliance Requirements: The shares involved in this financing will be privately placed under Section 4(a)(2) and Rule 506(b) of the Securities Act of 1933, meaning they are not registered and cannot be publicly sold in the U.S. without SEC registration, ensuring compliance with regulatory standards.
- Market Impact: Univest has successfully raised over $1.7 billion in capital for issuers globally since 2019, and this transaction further solidifies its position on Wall Street while potentially opening new growth opportunities for PMGC Holdings.
See More
SVM Machining Signs Long-Term Agreement with Turbo-Jet Products
- Long-Term Agreement Signed: SVM Machining's execution of a long-term agreement with Turbo-Jet Products will supply mission-critical aerospace and defense components, ensuring stable supply over the next five years, thereby enhancing SVM's position within the aerospace supply chain.
- Strategic Partnership: The agreement not only provides a framework for future purchase orders but also supports compliance with U.S. government and defense-related contracts, demonstrating SVM's commitment to meeting stringent regulations.
- Quality Certification Progress: SVM registered under the International Traffic in Arms Regulations (ITAR) as of March 20, 2026, and is actively pursuing AS9100 certification, which is expected to further enhance its competitiveness in regulated defense programs.
- Diverse Business Support: As a wholly-owned subsidiary of PMGC Holdings, SVM supports multiple critical industries, including medical technology, aerospace, and semiconductors, showcasing its robust production capabilities in a diversified market.
See More
PMGC Secures $40 Million Funding to Boost Acquisition Plans
- Funding Boost for Acquisitions: PMGC Holdings announced a $40 million equity purchase facility, with an initial tranche of approximately $10 million aimed at acquisitions, automation investments, and workforce development, enhancing its market position in the aerospace and defense sectors.
- Stock Price Rebound: Following the funding announcement, ELAB shares rose over 8% in morning trading on Friday, poised to end a three-session losing streak that had seen a decline of around 25%, indicating market confidence in the company's growth potential.
- Expansion Strategy: Since 2025, PMGC has expanded through acquisitions, adding three CNC precision manufacturing businesses and a specialty IT packaging firm, which strengthens its capabilities in complex machining and medical applications, thereby solidifying its competitive edge in the market.
- Market Sentiment Analysis: Despite the positive funding news, retail sentiment on Stocktwits remains bearish, reflecting the stock's recent underperformance, with a nearly 90% decline this year, as concerns about dilution threaten the capital structure.
See More
